Ovariectomy in aged versus young rats augments matrix metalloproteinase- mediated vasoconstriction in mesenteric arteries

Menopause

Volumn 17, Issue 3, 2010, Pages 516-523

  Lekontseva, Olga N ^a   Rueda Clausen, Christian F ^a   Morton, Jude S ^a   Davidge, Sandra T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Big endothelin 1; Matrix metalloproteinase; Menopause; Ovariectomy; Resistance arteries

Indexed keywords

ENDOTHELIN 1; ESTRADIOL; GELATIN; GELATINASE A; ILOMASTAT; MATRIX METALLOPROTEINASE;

AGE DISTRIBUTION; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HORMONE BLOOD LEVEL; MESENTERIC ARTERY; MYOGRAPHY; NONHUMAN; OVARY DISEASE; RAT; SPRAGUE DAWLEY RAT; UTERUS WEIGHT; VASCULAR TISSUE; VASOCONSTRICTION; ZYMOGRAPHY;

AGE FACTORS; AGING; ANIMALS; ENDOTHELIN-1; FEMALE; MATRIX METALLOPROTEINASES; MENOPAUSE; MESENTERIC ARTERIES; MODELS, ANIMAL; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION;

EID: 77952269617     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181c91f04     Document Type: Article

References (37)

1. Stice JP, Lee JS, Pechenino AS, Knowlton AA. Estrogen, aging and the cardiovascular system. Future Cardiol 2009;5:93-103.
2. Umetani M, Domoto H, Gormley AK, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 2007;13:1185-1192.
3. Xu HL, Baughman VL, Pelligrino DA. Estrogen replacement treatment in diabetic ovariectomized female rats potentiates postischemic leukocyte adhesion in cerebral venules. Stroke 2004;35:1974-1978.
4. Jacob MP. Extracellular matrix remodeling and matrix metalloprotein-ases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003;57:195-202.
5. Kunz J. Matrix metalloproteinases and atherogenesis in dependence of age. Gerontology 2007;53:63-73.
6. Schiffrin EL. Vascular stiffening and arterial compliance. Implications for systolic blood pressure. Am J Hypertens 2004;17:39S-48S.
7. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999;85:906-911.
8. Lekontseva O, Jiang Y, Davidge ST. Estrogen replacement increases matrix metalloproteinase contribution to vasoconstriction in a rat model of menopause. J Hypertens 2009;27:1602-1608.
9. Masson S, Latini R, Anand IS, et al. The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (VAL-HEFT). J Card Fail 2006; 12:375-380.
10. Watts SW, Thakali K, Smark C, Rondelli C, Fink GD. Big et-1 processing into vasoactive peptides in arteries and veins. Vascul Pharmacol 2007;47:302-312.
11. Arenas IA, Armstrong SJ, Xu Y, Davidge ST. Chronic tumor necrosis factor-> inhibition enhances no modulation of vascular function in estrogen-deficient rats. Hypertension 2005;46:76-81.
12. Chakrabarti S, Lekontseva O, Davidge ST. Estrogen is a modulator of vascular inflammation. IUBMB Life 2008;60:376-382.
13. Mark CJ, Tatchum-Talom R, Martin DS, Eyster KM. Effects of estrogens and selective estrogen receptor modulators on vascular reactivity in the perfused mesenteric vascular bed. Am J Physiol Regul Integr Comp Physiol 2007;293:R1969-R1975.
14. A mRNA expression in the aorta of ovariectomised New Zealand white rabbits. Gynecol Endocrinol 2009;25:175-182.
15. Pinna C, Cignarella A, Sanvito P, Pelosi V, Bolego C. Prolonged ovarian hormone deprivation impairs the protective vascular actions of estrogen receptor > agonists. Hypertension 2008;51:1210-1217.
16. Suzuki S, Brown CM, Dela Cruz CD, Yang E, Bridwell DA, Wise PM. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc Natl Acad Sci USA 2007;104:6013-6018.
17. Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause 2007;14:978-984.
18. Pedersen SH, Nielsen LB, Mortensen A, Nilas L, Ottesen B. Progestins oppose the effects of estradiol on the endothelin-1 receptor type A in coronary arteries from ovariectomized hyperlipidemic rabbits. Menopause 2008;15:503-510.
19. Xu JW, Ikeda K, Yamori Y. Genistein inhibits expressions of NADPH oxidase p22phox and angiotensin II type 1 receptor in aortic endothelial cells from stroke-prone spontaneously hypertensive rats. Hypertens Res 2004;27:675-683.
20. Jazbutyte V, Hu K, Kruchten P, et al. Aging reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female spontaneously hypertensive rats. Hypertension 2006;48:579-586.
21. Ishihata A, Katano Y. Role of angiotensin II and endothelin-1 receptors in aging-related functional changes in rat cardiovascular system. Ann N Y Acad Sci 2006;1067:173-181.
22. Stauffer BL, Westby CM, DeSouza CA. Endothelin-1, aging and hypertension. Curr Opin Cardiol 2008;23:350-355.
23. Thijssen DH, Rongen GA, van Dijk A, Smits P, Hopman MT. Enhanced endothelin-1-mediated leg vascular tone in healthy older subjects. J Appl Physiol 2007;103:852-857.
24. Bilsel AS, Moini H, Tetik E, Aksungar F, Kaynak B, Ozer A. 17A-estradiol modulates endothelin-1 expression and release in human endothelial cells. Cardiovasc Res 2000;46:579-584.
25. Dubey RK, Jackson EK, Keller PJ, Imthurn B, Rosselli M. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptorY independent mechanism. Hypertension 2001;37:640-644.
26. Wilbert-Lampen U, Seliger C, Trapp A, Straube F, Plasse A. Female sex hormones decrease constitutive endothelin-1 release via endothelial sigma-1/cocaine receptors: an action independent of the steroid hormone receptors. Endothelium 2005;12:185-191.
27. Anggrahini DW, Emoto N, Nakayama K, et al. Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation. Cardiovasc Res 2009;82: 143-151.
28. Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007;76:8-18.
29. Zhang Y, Stewart KG, Davidge ST. Estrogen replacement reduces age-associated remodeling in rat mesenteric arteries. Hypertension 2000;36: 970-974.
30. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008;153:1105-1119.
31. Matsumoto T, Kakami M, Kobayashi T, Kamata K. Gender differences in vascular reactivity to endothelin-1 (1-31) in mesenteric arteries from diabetic mice. Peptides 2008;29:1338-1346.
32. Arenas IA, Armstrong SJ, Xu Y, Davidge ST. Tumor necrosis factor-> and vascular angiotensin II in estrogen-deficient rats. Hypertension 2006;48:497-503.
33. Lam KK, Lee YM, Hsiao G, Chen SY, Yen MH. Estrogen therapy replenishes vascular tetrahydrobiopterin and reduces oxidative stress in ovariectomized rats. Menopause 2006;13:294-302.
34. 1-adrenergic responses in rat mesenteric arteries. Am J Physiol Heart Circ Physiol 2003;284:H1737-H1743.
35. Stice JP, Eiserich JP, Knowlton AA. Role of aging versus the loss of estrogens in the reduction in vascular function in female rats. Endocrinology 2009;150:212-219.
36. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstric-tion through the epidermal growth factorYreceptor pathway. Circ Res 2004;94:68-76.
37. Fernandez-Patron C. Therapeutic potential of the epidermal growth factor receptor transactivation in hypertension: a convergent signaling pathway of vascular tone, oxidative stress, and hypertrophic growth downstream of vasoactive g-protein-coupled receptors? Can J Physiol Pharmacol 2007;85:97-104.